Pharmaceutical

Merck to invest €300m in South Korean bioprocessing centre

Merck KGaA has announced an investment of over €300m ($326.1m) to establish a new bioprocessing production centre in Daejeon, South Korea.

Mar 22, 2024 - 00:00
Merck to invest €300m in South Korean bioprocessing centre
Merck KGaA has announced an investment of over €300m ($326.1m) to establish a new bioprocessing production centre in Daejeon, South Korea.
Read the original article

Tags:

Previous Article

Delivery tech remains challenging with gene therapies for brain disorders

Next Article

Donanemab: FDA AdCom will put spotlight on tau enrolment and ARIA concerns

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca reports positive Phase III results for Imfinzi in small cell lung cancer

AstraZeneca reports positive Phase III results for Imfi...

Apr 7, 2024

Synlogic’s SYNB1934 receives orphan drug status from US FDA

Synlogic’s SYNB1934 receives orphan drug status from US...

May 10, 2023

Teva and Sanofi conclude collaboration deal for anti-TL1A therapy

Teva and Sanofi conclude collaboration deal for anti-TL...

Dec 2, 2023